Gregory A. Winchell

1.3k total citations
32 papers, 1.1k citations indexed

About

Gregory A. Winchell is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, Gregory A. Winchell has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 8 papers in Pediatrics, Perinatology and Child Health and 8 papers in Epidemiology. Recurrent topics in Gregory A. Winchell's work include Antifungal resistance and susceptibility (15 papers), HIV/AIDS drug development and treatment (7 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Gregory A. Winchell is often cited by papers focused on Antifungal resistance and susceptibility (15 papers), HIV/AIDS drug development and treatment (7 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Gregory A. Winchell collaborates with scholars based in United States, Japan and Belgium. Gregory A. Winchell's co-authors include Paul Deutsch, Julie A. Stone, Howard Greenberg, Michael Hesney, Scott A. Waldman, Kenneth C. Lasseter, Stacy C. Dilzer, Peter Wickersham, Elizabeth Migoya and Goutam C. Mistry and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, PEDIATRICS and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Gregory A. Winchell

32 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory A. Winchell United States 15 684 354 224 223 158 32 1.1k
Goutam C. Mistry United States 15 326 0.5× 197 0.6× 346 1.5× 287 1.3× 131 0.8× 21 939
Michael Hesney United States 13 380 0.6× 234 0.7× 291 1.3× 20 0.1× 73 0.5× 25 896
José Ramón Azanza Perea Spain 18 276 0.4× 277 0.8× 281 1.3× 38 0.2× 93 0.6× 108 1.2k
Raul M. Alfaro United States 18 274 0.4× 187 0.5× 110 0.5× 65 0.3× 171 1.1× 25 981
Robert Kulawy United States 21 412 0.6× 383 1.1× 515 2.3× 55 0.2× 111 0.7× 36 1.3k
Pierre Comby France 9 292 0.4× 119 0.3× 87 0.4× 18 0.1× 71 0.4× 12 525
Caroline Perry United States 19 343 0.5× 272 0.8× 334 1.5× 591 2.7× 75 0.5× 48 1.8k
Lillian Ting Canada 15 537 0.8× 273 0.8× 135 0.6× 42 0.2× 54 0.3× 26 1.1k
Harin Karunajeewa Australia 23 246 0.4× 264 0.7× 105 0.5× 23 0.1× 150 0.9× 67 1.9k
Corstiaan Brass United States 16 458 0.7× 401 1.1× 80 0.4× 46 0.2× 74 0.5× 25 883

Countries citing papers authored by Gregory A. Winchell

Since Specialization
Citations

This map shows the geographic impact of Gregory A. Winchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory A. Winchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory A. Winchell more than expected).

Fields of papers citing papers by Gregory A. Winchell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory A. Winchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory A. Winchell. The network helps show where Gregory A. Winchell may publish in the future.

Co-authorship network of co-authors of Gregory A. Winchell

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory A. Winchell. A scholar is included among the top collaborators of Gregory A. Winchell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory A. Winchell. Gregory A. Winchell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Depei, Jianyu Weng, Junling Zhuang, et al.. (2022). Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections. Advances in Therapy. 39(4). 1697–1710. 1 indexed citations
2.
Iwasa, Takashi, et al.. (2022). Model‐Informed Dose Justifications of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection. The Journal of Clinical Pharmacology. 63(4). 421–434. 5 indexed citations
3.
Liu, Kai‐Yan, Depei Wu, Junmin Li, et al.. (2020). Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection. Advances in Therapy. 37(5). 2493–2506. 5 indexed citations
4.
Groll, Andreas H., Hisham Abdel‐Azim, Thomas Lehrnbecher, et al.. (2020). Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. International Journal of Antimicrobial Agents. 56(3). 106084–106084. 32 indexed citations
5.
Sun, Peng, Susan Li, Carole A. Sable, et al.. (2013). Caspofungin exposure‐response relationships in adult patients with mucosal or invasive candidiasis. Clinical Pharmacology in Drug Development. 3(1). 43–50. 1 indexed citations
6.
Migoya, Elizabeth, Goutam C. Mistry, Julie A. Stone, et al.. (2010). Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants. The Journal of Clinical Pharmacology. 51(2). 202–211. 27 indexed citations
7.
Stroh, Mark, Carol Addy, Yunhui Wu, et al.. (2009). Model-Based Decision Making in Early Clinical Development: Minimizing the Impact of a Blood Pressure Adverse Event. The AAPS Journal. 11(1). 99–108. 5 indexed citations
8.
Mistry, Goutam C., Elizabeth Migoya, Paul Deutsch, et al.. (2007). Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations. The Journal of Clinical Pharmacology. 47(8). 951–961. 49 indexed citations
9.
10.
Winchell, Gregory A., Goutam C. Mistry, Thomas Marbury, et al.. (2005). The Effect of Ketoconazole on the Pharmacokinetics of a Selective α1A‐Adrenoceptor Antagonist. The Journal of Clinical Pharmacology. 45(6). 699–703. 3 indexed citations
11.
Kraft, Walter K., Jacqueline B. McCrea, Gregory A. Winchell, et al.. (2004). Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. The Journal of Clinical Pharmacology. 44(3). 305–313. 27 indexed citations
12.
Stone, Julie A., Xin Xu, Gregory A. Winchell, et al.. (2004). Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma. Antimicrobial Agents and Chemotherapy. 48(3). 815–823. 111 indexed citations
13.
Bergshoeff, Alina S, Pieter L. A. Fraaij, Annemarie M. C. van Rossum, et al.. (2004). Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children. Antimicrobial Agents and Chemotherapy. 48(5). 1904–1907. 9 indexed citations
14.
Winchell, Gregory A., et al.. (2002). Cyclobenzaprine Pharmacokinetics, Including the Effects of Age, Gender, and Hepatic Insufficiency. The Journal of Clinical Pharmacology. 42(1). 61–69. 30 indexed citations
15.
Stone, JA, Peter Wickersham, Paul Deutsch, et al.. (2001). Drug interactions between caspofungin and tacrolimus. 41. 1. 17 indexed citations
16.
Wickersham, Peter, Paul Deutsch, Gregory A. Winchell, et al.. (2001). Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. 41. 1. 12 indexed citations
17.
Saah, Alfred J., et al.. (2001). Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 45(10). 2710–2715. 51 indexed citations
18.
Rodrigues, A. David, Gregory A. Winchell, & Michael R. Dobrinska. (2001). Use of In Vitro Drug Metabolism Data to Evaluate Metabolic Drug‐Drug Interactions in Man: The Need for Quantitative Databases. The Journal of Clinical Pharmacology. 41(4). 368–373. 32 indexed citations
19.
Hecken, Anne Van, Jules I. Schwartz, T. B. Tjandramaga, et al.. (1994). Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects. European Journal of Clinical Pharmacology. 46(2). 123–126. 8 indexed citations
20.
Winchell, Gregory A., et al.. (1993). Finasteride, A Steroid 5α‐Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine. The Journal of Clinical Pharmacology. 33(10). 967–970. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Goutam C. Mistry Breakdown of academic impact, for papers by Michael Hesney Breakdown of academic impact, for papers by José Ramón Azanza Perea Breakdown of academic impact, for papers by Raul M. Alfaro Breakdown of academic impact, for papers by Robert Kulawy Breakdown of academic impact, for papers by Pierre Comby Breakdown of academic impact, for papers by Caroline Perry Breakdown of academic impact, for papers by Lillian Ting Breakdown of academic impact, for papers by Harin Karunajeewa Breakdown of academic impact, for papers by Corstiaan Brass
Rankless by CCL
2026